Verastem, Inc. (VSTM)
Market Cap | 202.87M |
Revenue (ttm) | n/a |
Net Income (ttm) | -72.56M |
Shares Out | 200.86M |
EPS (ttm) | -0.37 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 84,076,159 |
Open | 1.00 |
Previous Close | 0.45 |
Day's Range | 0.46 - 1.21 |
52-Week Range | 0.29 - 1.47 |
Beta | 0.79 |
Analysts | Strong Buy |
Price Target | 3.00 (+197.03%) |
Earnings Date | May 9, 2023 |
About VSTM
Verastem, Inc., a development-stage biopharmaceutical company, focusing on developing and commercializing drugs for the treatment of cancer. Its product in development includes VS-6766, a dual rapidly accelerated fibrosarcoma (RAF)/mitogen-activated protein kinase (MEK) clamp that blocks MEK kinase activity and the ability of RAF to phosphorylate MEK. The company also engages in developing RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of VS-6766 and in combination wi... [Read more]
Financial Performance
In 2022, Verastem's revenue was $2.60 million, an increase of 26.45% compared to the previous year's $2.05 million. Losses were -$73.81 million, 3.67% more than in 2021.
Financial StatementsAnalyst Forecast
According to 4 analysts, the average rating for VSTM stock is "Strong Buy." The 12-month stock price forecast is $3.0, which is an increase of 197.03% from the latest price.
News

Updated Data from Part A of Verastem Oncology's RAMP 201 Trial Show an Objective Response Rate of 45% in Patients with Recurrent Low-Grade Serous Ovarian Cancer Treated with Avutometinib and Defactinib
BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced updated data from Part A of the on...

Verastem Oncology Appoints Karin Tollefson, PhD, to Board of Directors
BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced the appointment of Karin Tollefson ...

Verastem Oncology Reports First Quarter 2023 Financial Results and Highlights Recent Company Progress
BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today reported financial results for the first qua...

Verastem Oncology to Participate in Upcoming Investor Conferences
BOSTON--(BUSINESS WIRE)--Verastem Oncology, (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced that the Company will participate...

New Data from Interim Analysis of Verastem Oncology's RAMP 201 Trial Evaluating Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer to be Presented at the American Society of Clinical Oncology Annual Meeting
BOSTON--(BUSINESS WIRE)--Verastem Oncology, (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced that an abstract highlighting upd...

Verastem Oncology to Present at the Stifel 2023 Virtual Targeted Oncology Days
BOSTON--(BUSINESS WIRE)--Verastem Oncology, (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced that the Company will present at ...

Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced the grant of stock options to purch...

New Verastem Oncology Initiative, Let's Talk About LGSOC, Calls Attention to Rare Form of Ovarian Cancer
BOSTON--(BUSINESS WIRE)--Verastem Oncology, (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced the launch of Let's Talk About LG...

Verastem Oncology Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Recent Company Progress
BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today reported financial results for the three mon...

Top 3 stocks under $1 to buy in March
With the third month of 2023 already well underway, the ripple effect from the collapse of multiple banks in the United States is felt far and wide, leaving investors to wonder which stocks are worthy...

Verastem Oncology Outlines Key 2023 Strategic Priorities and Upcoming Catalysts for Advancing Avutometinib as a Backbone of Therapy for RAS Pathway-Driven Cancers
BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq:VSTM), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today outlined key strategic priorities and u...

Verastem Oncology Announces Up to $60 Million Private Placement Offering of Series B Convertible Preferred Stock
BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced that it has entered into a defini...

Verastem Oncology Announces Positive Data and Regulatory Update from Planned Interim Analysis of Registration-Directed Phase 2 RAMP-201 Trial of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer
BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announces positive interim data from Part ...

Verastem Oncology Appoints Rob Gagnon to Board of Directors
BOSTONBOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced the appointment of Robert G...

Verastem Oncology Reports Third Quarter 2022 Financial Results and Highlights Recent Company Progress
BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today reported financial results for the three mon...

Verastem Oncology Appoints Anil Kapur to Board of Directors
BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced the appointment of Anil Kapur to it...

Verastem Oncology Announces RAMP VS-6766 Clinical Trials and Corporate Updates
BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced an update on its RAMP (Raf And Mek ...

Verastem Oncology Reports Second Quarter 2022 Financial Results and Highlights Recent Company Progress
BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today reported financial results for the three mon...

RBC Says Verastem Interim Analysis In Ovarian Cancer Reinforces Enthusiasm
With the anticipation of a 2Q program update, Verastem Oncology (NASDAQ: VSTM) announced that its interim analysis findings for the RAMP 201 program for recurrent low-grade serous ovarian cancer (LGSO...

Verastem Oncology Provides Update on RAMP 201 Study Evaluating VS-6766 ± Defactinib in Low-Grade Serous Ovarian Cancer
BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for people living with cancer, today announced an update from an interim ana...

Verastem Oncology Awarded Pancreatic Cancer Action Network's First Therapeutic Accelerator Award to Evaluate the Combination of VS-6766 and Defactinib in Front-Line Metastatic Pancreatic Cancer
BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced that it has received the first “Th...

Verastem Oncology Reports First Quarter 2022 Financial Results and Highlights Recent Company Progress
BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today reported financial results for the three mon...

Verastem Announces $150M Debt Financing To Support VS-6766, Defactinib Development
Verastem Oncology Inc (NASDAQ: VSTM) entered into a credit facility with Oxford Finance LLC for up to $150 million to primarily support the continued development, commercial preparation, and potential...

Verastem Oncology Reports Fourth Quarter and Full Year 2021 Financial Results and Highlights Recent Company Progress
BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today reported financial results for the three mon...

Verastem Oncology Provides Financial Update to Support Development of VS-6766 and Defactinib in RAS Pathway-Driven Tumors
BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced it has entered into a credit facil...